The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that:
Introduction
Aqueous solubility and intestinal permeability of the active pharmaceutical ingredient (API), together with the dissolution of the formulated product, are three major factors which determine drug absorption and ultimately its efficacy. The Biopharmaceutics Classification System (BCS) classifies drug substances into four groups according to their solubility and permeability properties: class I (high permeability, high solubility), class II (high permeability, low solubility), class III (low permeability, high solubility) and class IV (low permeability, low solubility). 1 Overcoming the low permeability problem is primarily a task for formulation scientists, and much work has been targeting the development of permeability-enhancing excipients. 2 Improving the solubility of solid drug substances, on the other hand, is an important and topical research goal in the area of organic solid state chemistry, and cocrystallisation is emerging as an increasingly prominent approach to achieving this goal. Cocrystals can be broadly described as crystalline multi-component adducts comprising neutral molecules held together by noncovalent interactions. In pharmaceutical cocrystals, the key components are API molecules and appropriate benign coformer molecules, typically substances on the GRAS list.
3 Design and preparation of cocrystals are widely thought of as based on the supramolecular synthon approach 4 , i. e. on the existence of complementary functional groups in the API and coformer molecules. With compatible functional groups, noncovalent interactions (primarily hydrogen bonding) are likely to arise and lead to cocrystal formation.
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Furosemide (FS, Figure 1 ), 4-chloro-2-[(2-furanylmethyl)amino]-5-sulfamoylbenzoic acid, is a loop diuretic drug used for the treatment of hypertension and oedemas arising from cardiac, renal and hepatic failure. 5 It is a class IV drug according to the BCS, suffering from both low permeability and low solubility. 6 The furosemide permeability and delivery-related issues have been addressed by a number of approaches, the most recent ones being emulsification and the use of mesoporous materials as carriers. [7] [8] [9] Cocrystallisation is amongst methods with the potential to provide a significant improvement in solubility, according to the recent findings of
Goud et al. 10 The formation of cocrystals between furosemide and eight different coformers (caffeine, urea, p-aminobenzoic acid, acetamide, nicotinamide, isonicotinamide, adenine and cytosine) was reported and the improved solubility and dissolution of these materials relative to pure furosemide was demonstrated. However, only two of the compositions (caffeine and cytosine cocrystals) were obtained as single crystals which are needed for accurate structure determination by X-ray diffraction, for elucidation of the hydrogen bonding interactions leading to cocrystal formation and for structure-property correlations; in the remaining six cases, the cocrystal structures remained unknown.
A further problem arising from the absence of accurate crystal structures can be a limited ability to establish with a high degree of certainty the phase purity and identity of the bulk material characterised. Ueto et al. 11 have determined the crystal structures of four forms of the furosemide-nicotinamide cocrystals using laboratory powder X-ray diffraction. In this work, a large number of restraints were used in the Rietveld refinements of the non-hydrogen atoms (bond length and angle restraints, planar restraints on the phenyl, furan and pyridine rings, on carboxyl groups and on amide groups); all hydrogen atoms were placed geometrically and fixed 4 during the refinements. This again resulted in a lack of accurate and precise structural information needed to establish the key intermolecular interactions.
In this paper we report successful crystal growth of four furosemide cocrystals, prepared with Structure solution was carried out using SIR92 and structure refinement on F 2 was carried out using CRYSTALS. 13, 14 Positional and anisotropic atomic displacement parameters (adps) were refined for all non-hydrogen atoms. A mixed hydrogen atom treatment was used: most hydrogen atoms were placed geometrically treated using a riding model, except for those involved in hydrogen bonding, whose fractional coordinates and isotropic atomic displacement parameters were freely refined.
All crystallographic details are given in Table 1.   7 2.4. Powder X-ray diffraction: Powder X-ray diffraction data were collected on a Bruker D8 ADVANCE diffractometer (CuK α1,2 radiation) and a LynxEye detector. Patterns were recorded in ranges between 2 and 60° using a step size of 0.014 °. Data analysis was carried out using Topas-Academic software. 15 2.5. Solid state NMR: Solid state C 13 NMR spectra were recorded on a Varian VNMRS 400
spectrometer. CP-MAS measurements were carried out using a 6.8 kHz spinning rate and a contact time of 1.0 ms. Spectra were referenced to neat tetramethylsilane.
2.6. Thermal analysis: DSC measurements were carried out using TA DSC Q1000 instrument equipped with a nitrogen purge gas. 4-5 mg of sample was typically used for analysis. The heating rate was 10 o /min. 
Results and discussion
The furosemide molecule possesses a considerable potential for intermolecular interactions with coformer molecules via three functional groups which can give rise to hydrogen bonding (the sulfonamide group SO 2 NH 2 , the carboxyl group COOH and the NH group); these are complemented by the coformer molecules chosen (Fig. 1) . The variety of hydrogen bonding interactions found in the cocrystals characterised in this work are depicted in Fig. 2 and discussed for each individual cocrystal separately. 
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The hydrogen bonding parameters derived from our single crystal work shed new insight into intermolecular interactions in this cocrystal, which wasn't attainable from the heavily restrained
powder diffraction based refinement. 11 The most notable and interesting new feature that our analysis reveals concerns the interaction in synthon V. This is an O-H···N hydrogen bond with a D···A distance of 2.55 Å and a D-H···A angle close to 180 o , which classifies it as a short strong hydrogen bond (SSHB). 16 Table 3 ). Finally, FS molecules interact via Cl(1)···O(5) weak halogen bonds, which, with Cl···O distances of 3.23 Å, appear to be at the boundary between bonding and non-bonding. Our attempts to prepare bulk FS-INA 1:1 material by neat and wet grinding resulted in the formation of the 2:1 cocrystal (vide infra). For reference we give the calculated PXRD pattern obtained using the model derived from the single crystal X-ray structure analysis (Fig. 7 ). (Fig. 8a-b) ; the corresponding torsion angle in FS2 is -83 o , leading to a bent molecule (Fig. 8c-d) . Similar bent conformations of the furosemide molecule are found in triclinic forms I and III of pure furosemide and also in the furosemidecaffeine cocrystals. (Fig. 10) . The identity of this impurity is unknown; however, it is not any of the starting materials or the 1:1 FS-INA cocrystal. Given the preparation conditions, the most likely explanation is the formation of a very small amount of an acetone solvate. The fact that a single melting endotherm is observed in the DSC trace of this sample (vide infra) confirms that it is an essentially single phase product, with any impurity at a very minor level. Solid state 13 C NMR was performed on FS, INA, on the lightly mixed physical mixture of the two starting components and on the cocrystal product (Fig. 11a) . The latter shows a number of chemical shift changes in the spectrum relative to pure FS and INA. In contrast, the spectrum of a 1:1 physical mixture of the reagents corresponds to the sum of the individual spectra of FS and PABA. 
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The appearance of the PXRD pattern shown in Fig. 10 suggests that an amorphous component exists in the bulk product, which is not surprising in a product prepared by grinding of soft organic materials. This, however, necessitates additional characterisation by complementary techniques to rule out the possibility that the amorphous component represents an unwanted impurity. In this case, the NMR spectra and DSC curve together confirm that any amorphous component in the sample is the target cocrystal itself. (Fig. 11 ). FS-PABA bulk material characterisation: The liquid-assisted grinding procedure yielded an off-white (pale pink) powder. The structural model obtained from the single crystal X-ray analysis was used to perform Rietveld fitting of the observed PXRD pattern, which confirmed the product obtained is single phase (Fig. 13 ). 
Structure-property relationships
Goud et al. 10 have reported two sets of pharmacologically relevant properties, namely solubility and intrinsic dissolution rate in 10% ethanol -water, for pure FS and a number of its cocrystal compositions. The crystal structures of only two cocrystals (furosemide with caffeine, FS-CAFF and with cytosine, FS-CYT) were known at the time, which limited the scope for increase in aqueous solubility of FS-CYT relative to pure furosemide to the fact that this composition forms a salt, i.e. the proton from the COOH group of FS is transferred to the basic ring N atom of the cytosine molecule. Secondly, they proposed that the stability of FS-CAFF, FS-CYT and FS-ADEN in 10% ethanol -water slurry was a consequence of these being congruently dissolving systems, made up of components of similar solubility. However, they found FS-PABA cocrystal to be an exception from this trend, being unstable and converting to furosemide within 24 hours, and also displaying the smallest improvement in solubility and intrinsic dissolution rate relative to pure FS.
The details of crystal structures and hydrogen bonding presented on our work can shed light on these observations. Firstly, none of the four compositions whose structures have been determined form salts, and this correlates well with their reported aqueous solubility values being lower than that of FS-CYT, although they are still higher than that of pure furosemide. Secondly, the FS-PABA structure is unique among the furosemide cocrystals in that the intermolecular interactions are stronger between pairs of molecules of the same component than between the API and the coformer molecules. As shown in Table 5 However, future work on this system includes measurements of solubility, intrinsic dissolution rate and stability using the same methodology employed by Goud et al. 10 , in order to acquire data for meaningful comparisons.
Conclusions
Several different synthons are present in the forms of FS analysed in this work, as summarised in Table 6 . However, some general trends can be observed. Synthons II, III and V are formed in most of the cocrystals containing the relevant functional groups. Comparisons of bond lengths and angles suggest that all occurrences of II and III are of moderate strength; however, in two out of three occurrences, synthon V displays very short D···A distances (d N···O = 2.55 Å) between the best hydrogen bonding donor and the best hydrogen bonding acceptor in each case, implying strong hydrogen bonding interactions. 
